Featured Studies Results
Study Type: Treatment
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment
Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)
Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment
Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)
https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back
Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)
Treatment
Study for relapsed platinum-sensitive ovarian cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)
Treatment
Treatment study for people with advanced or metastatic cancers
Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)
https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer
Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)
Treatment
Phase 3 treatment study for high-risk prostate cancer
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery
Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)
https://www.facingourrisk.org/research-clinical-trials/study/375 /treating-advanced-endometrial-or-ovarian-cancer-with-targeted-therapies-combomatch
Clinicaltrials.gov identifier:
NCT05554328 (https://clinicaltrials.gov/show/NCT05554328)
Treatment
Phase 2 treatment study for recurrent endometrial cancer
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/314 /neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer
Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01
Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)
Treatment
Post-treatment study to monitor for recurrence
Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
https://www.facingourrisk.org/research-clinical-trials/study/370 /comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01
Clinicaltrials.gov identifier:
NCT07044336 (https://clinicaltrials.gov/show/NCT07044336)
Treatment
Phase 3 treatment study for metastatic endometrial cancer
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
https://www.facingourrisk.org/research-clinical-trials/study/408 /treating-advanced-solid-tumors-with-the-rason-inhibitor-daraxonrasib-combined-with-a-targeted-immunotherapy-ivonescimab
Clinicaltrials.gov identifier:
NCT07397338 (https://clinicaltrials.gov/show/NCT07397338)
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/387 /comparing-a-new-drug-palazestrant-to-standard-treatment-for-advanced-breast-cancer
Clinicaltrials.gov identifier:
NCT06016738 (https://clinicaltrials.gov/show/NCT06016738)
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
https://www.facingourrisk.org/research-clinical-trials/study/409 /treating-advanced-solid-tumors-with-a-kras-g12c-mutation-using-targeted-therapies-called-rason-inhibitors
Clinicaltrials.gov identifier:
NCT06128551 (https://clinicaltrials.gov/show/NCT06128551)
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer
Clinicaltrials.gov identifier:
NCT06411691 (https://clinicaltrials.gov/show/NCT06411691)
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
https://www.facingourrisk.org/research-clinical-trials/study/388 /comparing-hormone-therapy-with-and-without-chemotherapy-for-premenopausal-breast-cancer-ofset
Clinicaltrials.gov identifier:
NCT05879926 (https://clinicaltrials.gov/show/NCT05879926)
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.